PS
MRNA icon

PayPay Securities’s Moderna MRNA Stock Holding History

PayPay Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910 Sell
13
-6
-32% -$310 0.02% 252
2026
Q1 		$1.04K Sell
19
-20
-51% -$933 0.04% 243
2025
Q4 		$1.15K Sell
39
-1
-3% -$27 0.03% 246
2025
Q3 		$1.04K Buy
40
+15
+60% +$418 0.04% 214
2025
Q2 		$690 Buy
25
+5
+25% +$132 0.03% 228
2025
Q1 		$586 Sell
20
-4
-17% -$142 0.03% 247
2024
Q4 		$998 Buy
24
+13
+118% +$621 0.04% 215
2024
Q3 		$735 Sell
11
-39
-78% -$3.58K 0.07% 115
2024
Q2 		$5.94K Sell
50
-9
-15% -$1.14K 0.5% 45
2024
Q1 		$6.29K Sell
59
-11
-16% -$1.11K 0.31% 73
2023
Q4 		$7.06K Sell
70
-62
-47% -$5.21K 0.35% 55
2023
Q3 		$13.6K Buy
132
+124
+1,550% +$13.8K 0.62% 38
2023
Q2 		$972 Sell
8
-9
-53% -$1.2K 0.06% 152
2023
Q1 		$2.61K Sell
17
-3
-15% -$495 0.17% 120
2022
Q4 		$3.59K Buy
+20
New +$3.27K 0.24% 110

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

PayPay Securities's MRNA Position: Q2 2026 in Review

PayPay Securities reduced its Moderna (MRNA) stake by 32% in Q2 2026, selling an estimated $310 and leaving 13 shares worth $910. The position accounts for 0.02% of the portfolio, ranked #252.

PayPay Securities first reported a position in MRNA in Q4 2022 and has held it in 15 quarters since. The position peaked at $13.6K in Q3 2023. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • PayPay Securities held 13 shares of Moderna worth $910 as of Q2 2026.
  • PayPay Securities sold 6 Moderna shares in Q2 2026, an estimated $310.
  • Moderna made up 0.02% of PayPay Securities's portfolio in Q2 2026, its #252 holding.
  • PayPay Securities first reported a position in Moderna in Q4 2022 and has held it in 15 quarters since.
  • PayPay Securities's Moderna position peaked at $13.6K in Q3 2023.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on PayPay Securities's 13F filing for Q2 2026, filed 23 Jul 2026.